A Phase I study of adjuvant chemotherapy with gemcitabine plus S-1 in patients with biliary tract cancer undergoing curative resection without major hepatectomy.

Trial Profile

A Phase I study of adjuvant chemotherapy with gemcitabine plus S-1 in patients with biliary tract cancer undergoing curative resection without major hepatectomy.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Sep 2016

At a glance

  • Drugs Gemcitabine (Primary) ; Gimeracil/oteracil/tegafur (Primary)
  • Indications Biliary cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 31 Aug 2016 Status changed from recruiting to active, no longer recruiting.
    • 22 Oct 2012 Planned end date (Mar 2017) added as reported by ClinicalTrials.gov.
    • 22 Oct 2012 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT01713387).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top